Canada Markets closed

Eli Lilly and Company (LLY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
245.58-2.30 (-0.93%)
At close: 04:02PM EST
246.08 +0.50 (+0.20%)
After hours: 06:37PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close247.88
Bid245.52 x 900
Ask245.56 x 800
Day's Range243.08 - 253.48
52 Week Range144.00 - 275.87
Avg. Volume2,861,259
Market Cap235.517B
Beta (5Y Monthly)0.24
PE Ratio (TTM)36.76
EPS (TTM)6.68
Earnings DateJan. 27, 2022 - Jan. 31, 2022
Forward Dividend & Yield3.40 (1.57%)
Ex-Dividend DateMay 13, 2021
1y Target Est262.24
  • Reuters

    UPDATE 1-FDA clears use of Lilly's COVID-19 antibody therapy for kids

    The U.S. Food and Drug Administration on Friday authorized the use of Eli Lilly's COVID-19 dual-antibody therapy in treating mild to moderate symptoms in all children, including newborns, who are at risk of severe illness. The therapy, bamlanivimab plus etesevimab, was previously authorized for children aged 12 years and older and weighed at least 88 pounds. "Children under one year of age, who are exposed to the virus that causes COVID-19, may be at particularly high risk for severe COVID-19 and this authorization addresses the medical needs of this vulnerable population," said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.

  • Reuters

    Mexico approves emergency use of Lilly's COVID-19 treatment

    Mexico's health regulator Cofepris said on Wednesday it had approved U.S. pharmaceutical firm Eli Lilly and Co's antibody treatment against COVID-19 for emergency use with infected patients at risk from comorbidities. Cofepris said in a statement it had granted the emergency use of Lilly's injectable combination of bamlanivimab and etesevimab to treat mild to moderate cases of coronavirus in people above the age of 12 who weigh at least 40 kilograms. The U.S. Food and Drug Administration had previously approved emergency use of the combination.

  • Zacks

    Merck (MRK) Up as COVID Pill Gets FDA Panel's Positive Vote

    An FDA committee voted 13-0 to recommend authorization of Merck's (MRK) antiviral pill to treat COVID-19.